☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Pegfilgrastim
Real-World Study Demonstrated Economic Benefits of Pegfilgrastim Biosimilar for the Prevention of Febrile Neutropenia
April 18, 2022
Sandoz Receives Health Canada's Approval to Launch Ziextenzo (biosimilar- pegfilgrastim) and Riximyo (biosimilar- rituximab) in Ca...
June 10, 2020
Insights+ Key Biosimilars Events of May 2020
June 5, 2020
Sandoz's Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia
November 27, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.
